BioSpace News Archive

Royal Philips, a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an independent consensus study of 32 leading wound care clinicians in Diagnostics1.

OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to immunosuppressive myeloid targets for cancer immunotherapy, announced the appointment of Sean A. McCarthy, D. Phil., as an Independent Director to its Board of Directors.

Microbix Biosystems Inc. announces the appointment of Thomas Scientific LLC as distributor of Microbix’s quality assessment products (QAPs™) for the United States.

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it has dosed the first patient in a Phase 1/2 study to evaluate the efficacy, safety and pharmacokinetics/pharmacodynamics of NGM707 when given alone or in combination with KEYTRUDA®, an anti- PD-1 antibody.

Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 p.m. Eastern Time.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation, to be held virtually from July 2-3 and 8-10.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference

Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference: